CST, 89500S, RAI17/ZMIZ1 (E2X3X) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying RAI17/ZMIZ1. Validated for Western Blotting,Immunoprecipitation,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, RAI17/ZMIZ1 (E2X3X) Rabbit Monoclonal Antibody (CST #89500) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:100 - 1:400 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin) Specificity / Sensitivity RAI17/ZMIZ1 (E2X3X) Rabbit Monoclonal Antibody recognizes endogenous levels of total RAI17/ZMIZ1 protein. Species Reactivity: Human, Mouse, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro902 of human RAI17/ZMIZ1 protein. Background ZMIZ1, also known as ZIMP10 or RAI17, is a member of the Protein Inhibitor of Activated STAT (PIAS)-like family of transcriptional coregulators (1). ZMIZ1 was initially discovered as a novel coregulator of the androgen receptor (AR) and was shown to augment AR activity by enhancing sumoylation of the receptor (2). Subsequent studies have shown that ZMIZ1 can also act as a transcriptional coactivator of p53 (3) and SMAD3 (4). During thymopoiesis, ZMIZ1 was shown to promote pre-T-cell proliferation through cooperative induction of a subset of NOTCH target genes (5). In T-cell acute lymphoblastic leukemia (T-ALL) cells, ZMIZ1 was shown to engage directly with NOTCH1 through an N-terminal tetratricopeptide repeat (TPR) domain, facilitating its recruitment to a long-range acting enhancer element to promote transcription and activity. Moreover, inhibition of ZMIZ1 impaired the initiation and maintenance of NOTCH-induced T-ALL (6). Although NOTCH1 appears to rely on ZMIZ1 to selectively amplify an oncogenic subset of target genes, research studies suggest ZMIZ1 is not involved in NOTCH-mediated intestinal homeostasis or myeloid suppression, suggesting that therapeutic strategies targeting ZMIZ1 may provide an opportunity to indirectly target NOTCH-driven cancers, with reduced adverse effects (7). Alternate Names FLJ00092 protein; FLJ13541; hZIMP10; KIAA1224; MIZ; NEDDFSA; PIAS-like protein Zimp10; RAI17; retinoic acid induced 17; Retinoic acid-induced protein 17; RP11-519K18.1; TRAFIP10; ZIMP10; Zinc finger MIZ domain-containing protein 1; zinc finger MIZ-type containing 1; zinc finger-containing, Miz1, PIAS-like protein on chromosome 10; zinc finger, MIZ-type containing 1; ZMIZ1 Specification REACTIVITY: H M Mk SENSITIVITY: Endogenous MW (kDa): 120, 130 Source/Isotype: Rabbit IgG